Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Non-Current Assets (2016 - 2025)

Coherus Oncology's Non-Current Assets history spans 13 years, with the latest figure at $51.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 51.72% year-over-year to $51.6 million; the TTM value through Dec 2025 reached $227.4 million, down 54.16%, while the annual FY2025 figure was $51.6 million, 51.72% down from the prior year.
  • Non-Current Assets for Q4 2025 was $51.6 million at Coherus Oncology, down from $55.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $154.0 million in Q4 2023 and bottomed at $51.6 million in Q4 2025.
  • The 5-year median for Non-Current Assets is $85.3 million (2023), against an average of $93.5 million.
  • The largest annual shift saw Non-Current Assets skyrocketed 57.3% in 2024 before it plummeted 59.14% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $77.0 million in 2021, then rose by 29.35% to $99.6 million in 2022, then surged by 54.57% to $154.0 million in 2023, then plummeted by 30.54% to $107.0 million in 2024, then crashed by 51.72% to $51.6 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Non-Current Assets are $51.6 million (Q4 2025), $55.6 million (Q3 2025), and $59.3 million (Q2 2025).